more MSM, PrEP users and clients notified for or with symptoms of STI were seen during- and post-lockdown compared to pre-lockdown. Chlamydia positivity was around 18% among heterosexual men and 15% among women from 2016–2019, and increased to 21.1% and 16.6% respectively in 2020. Positivity increased during lockdown, up to 32% among heterosexual men, followed by decreases post-lockdown to pre-lockdown levels. Among MSM, the increase during lockdown was smaller, only slightly affecting overall positivity in 2020. Gonorrhoea positivity also increased during lockdown, causing further increasing trends among heterosexuals from 1.8% in 2011 to 2.2% in 2020 and among MSM from 9.0% to 12.1%. Syphilis positivity among MSM fluctuated between 2.0% and 2.9% in 2011–2020. Positivity peaked (6.7%) during lockdown, while the number of diagnoses was similar to pre-lockdown. In contrast, HIV positivity continued to decrease from 2.0% to 0.3% among MSM in 2011–2020.

Conclusion Prioritising persons at highest risk caused decreases in diagnoses, especially chlamydia and gonorrhoea, but increases in positivity. More information is needed to understand transmission dynamics, including testing at GPs, self-testing and sexual behaviour during coronavirus pandemic.

**VALUE OF CLIA SEROCONVERSION WITH NEGATIVE RPR AND IMMUNOBLOT FOR THE DIAGNOSIS OF EARLY SYPHILIS**

1S Nieuwenburg*, 1P Huurdeman, 1,2,3H de Vries, 1,4A van Dam. 1Department of Infectious Diseases, Public Health Service Amsterdam, The Netherlands; 2Amsterdam institute for Infection and Immunity, Amsterdam UMC, The Netherlands; 3Department of Dermatology, Amsterdam UMC, The Netherlands; 4Department of Medical Microbiology, Amsterdam UMC, The Netherlands

Introduction An isolated CLIA seroconversion (i.e. CLIA-reactive, immunoblot non-reactive, RPR non-reactive, with a previous negative CLIA) could indicate a false positive result or early incubating syphilis. To confirm early syphilis, follow-up appointments are often needed. We wanted to evaluate the diagnostic value of such seroconversions.

Methods We included every patient with a positive CLIA (Liaison) and a negative RPR and immunoblot visiting the STI clinic (To) between January 2014 to April 2020, and a preceding visit with a negative CLIA in the 6 months prior to the initial consultation (T-1). If available, a follow-up appointment in the 2 months after the initial consultation (T1) was included. If darkfield microscopy (DFM) or PCR for Treponema pallidum was positive at T0, diagnosis of syphilis was confirmed. This also applied to a positive RPR and/or immunoblot in the T1 consultation.

Results We included 91 participants with an isolated CLIA seroconversion. The value of the CLIA seroconversion in 19/91 (21%) of the study population could not be established, since they had no positive PCR or DFM ulcer sample at To and had no T1 consultation. Of the remaining 72 patients, 54 (75%) the CLIA seroconversion was confirmed. 28/54 persons (52%) had a PCR or DFM confirmation in the initial consultation and 26/54 persons (48%) had a serologic confirmation in the follow-up appointment. In 18/72 (25%) persons the CLIA seroconversion was regarded as false positive reaction since no seroconversion in RPR or immunoblot was seen at T1.

Conclusion Of the evaluable patients with a CLIA seroconversion, 75% had an early incubating syphilis infection. 48% of these patients would benefit from presumptive treatment, since they had no signs of primary syphilis at the moment of the CLIA seroconversion. However, 25% had a false positive result, thus would receive unnecessary presumptive treatment.
Background It is estimated that everyday over 1 million individuals contract a curable sexually transmitted infection (STI) worldwide. For an appropriate STI treatment, it is necessary to have an accurate diagnosis. The Alinity m STI assay is a multiplex RT-PCR assay that identifies four STI pathogens: Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), Trichomonas vaginalis (TV), and Mycoplasma genitalium (MG) in a single (115 min) reaction. The aim of this study was to evaluate the assay clinical performance.

Methods Clinical performance of Alinity m STI assay was assessed using 201 residual clinical samples [119 urine and 82 in gynecological specimens] and compared with Abbott Real-Time CT/NG assay and XGEN MULTI UP test (Mobius Life Science) for TV/MG. Precision and reproducibility were evaluated by testing panel members in contrived swab. Five panel members (PM) were tested in 12 replicates in two days: PM1=CT, PM2=NG, PM3=TV, PM4=MG and PM5=CT/NG-TV/MG at 2X claimed LoD.

Results For CT, the positive (PPA) agreement and negative (NPA) agreements were 95% and 100% respectively. For NG, the PPA was 94% for urine and 100% for gynecological specimens, and NPA was 99% and 100%, respectively. For MG, PPA and NPA were 100%. For TV, NPA was 100% (no positive result obtained). Co-infection with MG was observed in 5% of CT or NG positive samples. The overall agreement for both sample types and the four organisms was 98.5% (516/524). All panel members were detected and accurately identified, individually (PM1–4) or in the presence of the other three pathogens (PM5).

Conclusion The Alinity m STI assay showed excellent agreement (97–100%) between methods and streamlines laboratory workflow with simultaneous detection of 4 pathogens in a single reaction from the same sample. This assay allows rapid infection identification supporting clinicians to properly treat patients, especially when a co-infection is present.

P271

SEXUAL HEALTH SERVICE ADAPTATIONS TO THE CORONAVIRUS DISEASE 2019 (COVID-19) PANDEMIC IN AUSTRALIA: A NATIONWIDE ONLINE SURVEY

Background We aimed to examine the changes public sexual health services across Australia made during the national lockdown (March-May 2020) due to the COVID-19 pandemic.

Methods From July-August 2020, we emailed a link to an online survey to 21 sexual health clinic directors/managers who were part of the Australian Collaboration for Coordinated Enhanced Sentinel Surveillance of Sexually Transmissible Infections and Blood-borne Viruses (ACCESS) network.

Results All 20 participating clinics remained open but reported changes during the lockdown, including suspension of walk-in services in 8 clinics.

Some clinics stopped offering asymptomatic screening for heterosexuals (n=11), men who have sex with men (MSM) (n=3), or transgender persons (n=2). Most clinics offered a mix of telehealth and face-to-face consultations for asymptomatic MSM (n=11), asymptomatic transgender persons (n=12), post-exposure prophylaxis (PEP) prescription (n=13) or to initiate pre-exposure prophylaxis (PrEP) (n=14). People who were symptomatic for STIs and contacts of STIs were offered face-to-face and telehealth consultations across all clinics. Seven clinics suspended STI test-of-cure consultations and four clinics suspended hepatitis vaccinations for people not living with HIV. Nineteen clinics reported delays in testing and 13 reported limitations in testing during lockdown. Most clinics changed to phone consultations for HIV

A130